Prof. Sir Steve Jackson’s research and discoveries in protein ubiquitylation and deubiquitylation led to the founding of Mission to explore new therapeutic opportunities across various disease areas.

Sir Steve Jackson FRS, FMedSci is the University of Cambridge Frederick James Quick Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute and Associate Group Leader at the Gurdon Institute. As a pioneer in the field of DNA repair and DNA-damage signalling, Steve Jackson’s research has shaped our understanding of cellular responses to DNA damage and of how defects in these responses contribute to disease. Steve founded KuDOS Pharma that was acquired by AstraZeneca in 2006. Olaparib, which was developed by KuDOS, was approved for advanced BRCA+ ovarian cancer in USA and Europe in 2014.

Steve carried out his post-doctoral training in the lab of Professor Robert Tjian at Berkeley, USA. He obtained his BSc in Biochemistry from Leeds University, UK and his PhD from Edinburgh University. He is a fellow of both the Royal Society and the UK Academy of Medical Sciences.